SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology & Drugs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: 2MAR$ who wrote (224)2/28/2004 5:03:57 PM
From: 2MAR$  Read Replies (1) of 232
 
1/28 CHIR $55~$48 CHIR reports in-line Q4 EPS (CHIR) 51.25 +0.36: Reports Q4 (Dec) earnings of $0.29 per share, in line with the Reuters Research consensus of $0.29; total revenues rose 55.7% year/year to $554.6 mln vs the $480.4 mln consensus (may not be comparable).

Notable Mentions: CHIR, COF : Lehman says Chiron's (CHIR) Q4 results exemplify a lack of any sustainable high-growth drivers or highly-differentiated products that would warrant industry-avg valuation multiples; with the final qtr now booked incorporating the flu vaccine component of the Powderject acquisition, firm thinks the co looks to be entering a lull in terms of top-line growth, although an acquisition could alter that dynamic; maintains Underweight rating, raises target to $42 from $38...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News